Consulta: subjectFacets:"Von Willebrand factor"
Registros recuperados: 7
Data/hora: 16/06/2024 03:30:44

Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease
Provedor de dados: 56
Autores: Soares,R.P.S.; Bydlowski,S.P.; Nascimento,N.M.; Thomaz,A.M.; Bastos,E.N.M.; Lopes,A.A.
Changes in plasma von Willebrand factor concentration (VWF:Ag) and ADAMTS-13 activity (the metalloprotease that cleaves VWF physiologically) have been reported in several cardiovascular disorders with prognostic implications. We therefore determined the level of these proteins in the plasma of children with cyanotic congenital heart disease (CCHD) undergoing surgical treatment. Forty-eight children were enrolled (age 0.83 to 7.58 years). Measurements were performed at baseline and 48 h after surgery. ELISA, collagen-binding assays and Western blotting were used to estimate antigenic and biological activities, and proteolysis of VWF multimers. Preoperatively, VWF:Ag and ADAMTS-13 activity were decreased (65 and 71% of normal levels considered as 113...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: ADAMTS-13; Von Willebrand factor; Congenital heart disease; Thrombosis; Cardiac surgery.
Ano: 2013
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2013000400375

Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease
Provedor de dados: 56
Autores: Lopes,A.A.; Barreto,A.C.; Maeda,N.Y.; Cícero,C.; Soares,R.P.S.; Bydlowski,S.P.; Rich,S.
Biomarkers have been identified for pulmonary arterial hypertension, but are less well defined for specific etiologies such as congenital heart disease-associated pulmonary arterial hypertension (CHDPAH). We measured plasma levels of eight microvascular dysfunction markers in CHDPAH, and tested for associations with survival. A cohort of 46 inoperable CHDPAH patients (age 15.0 to 60.2 years, median 33.5 years, female:male 29:17) was prospectively followed for 0.7 to 4.0 years (median 3.6 years). Plasma levels of von Willebrand factor antigen (VWF:Ag), tissue plasminogen activator (t-PA) and its inhibitor (PAI-1), P-selectin, reactive C-protein, tumor necrosis factor alpha, and interleukin-6 and -10 were measured at baseline, and at 30, 90, and 180 days in...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Pulmonary hypertension; Congenital heart disease; Eisenmenger syndrome; Endothelial dysfunction; Von Willebrand factor; Th2 cytokine response.
Ano: 2011
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011001200011

Association studies between -1185A/G von Willebrand factor gene polymorphism and coronary artery disease
Provedor de dados: 56
Autores: Simon,D.; Paludo,C.A.; Ghisleni,G.C.; Manfroi,W.C.; Roisenberg,I.
High levels of von Willebrand factor (vWF) have been associated with cardiovascular disease. The A allele of the -1185A/G polymorphism in the 5'-regulatory region of the vWF gene was associated with the highest plasma vWF levels in a normal population. To examine the association between -1185A/G polymorphism and coronary artery disease (CAD), 173 Brazilian Caucasian subjects submitted to coronary angiography were studied. Of these, 57 (33%) had normal coronary arteries (control group) and 116 (67%) had CAD (patient group). Plasma vWF levels were higher in patients (145 U/dl) than in controls (130 U/dl), but the differences were significant only for O blood group subjects. Polymerase chain reaction amplification of the 864-bp vWF promoter region followed by...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Von Willebrand factor; Coronary artery disease; DNA polymorphisms; Risk factor.
Ano: 2003
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2003000600005

Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension: a placebo-controlled study
Provedor de dados: 56
Autores: Barreto,A.C.; Maeda,N.Y.; Soares,R.P.S.; Cícero,C.; Lopes,A.A.
We investigated whether chronic rosuvastatin administration could improve the abnormalities of the circulating levels of vascular dysfunction markers in pulmonary arterial hypertension (PAH). Sixty patients, aged 13 to 60 years, with idiopathic (N = 14) or congenital heart disease-associated PAH (N = 46) were equally but randomly assigned to rosuvastatin treatment (10 mg a day, orally) or placebo for 6 months in a blind fashion. Plasma levels of P-selectin, tissue-plasminogen activator and its inhibitor as well as von Willebrand factor antigen were measured by enzyme-linked immunoassay before and after 1, 3, and 6 months of treatment. Baseline levels of biomarkers were elevated (68, 16, 45 and 46% increase relative to controls, for P-selectin, von...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Pulmonary hypertension; Statins; Endothelial dysfunction; P-selectin; Tissue-plasminogen activator and inhibitor; Von Willebrand factor.
Ano: 2008
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000800003

A mathematical framework for group analysis of von Willebrand factor multimeric composition following luminography
Provedor de dados: 56
Autores: Lopes,A.A.; Soares,R.P.S.; Maeda,N.Y.
The objective of the present study was to establish a method for quantitative analysis of von Willebrand factor (vWF) multimeric composition using a mathematical framework based on curve fitting. Plasma vWF multimers from 15 healthy subjects and 13 patients with advanced pulmonary vascular disease were analyzed by Western immunoblotting followed by luminography. Quantitative analysis of luminographs was carried out by calculating the relative densities of low, intermediate and high molecular weight fractions using laser densitometry. For each densitometric peak (representing a given fraction of vWF multimers) a mean area value was obtained using data from all group subjects (patients and normal individuals) and plotted against the distance between the peak...
Tipo: Info:eu-repo/semantics/other
Palavras-chave: Von Willebrand factor; Luminography; Densitometry; Curve fitting; Pulmonary hypertension.
Ano: 2002
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2002001100002

von Willebrand factor antigen levels in plasma of patients with malignant breast disease
Provedor de dados: 56
Autores: Röhsig,L.M.; Damin,D.C.; Stefani,S.D.; Castro Jr.,C.G.; Roisenberg,I.; Schwartsmann,G.
von Willebrand factor (vWF) is a protein that mediates platelet adherence to the subendothelium during primary hemostasis. High plasma vWF concentrations have been reported in patients with various types of cancer, such as head and neck, laryngeal and prostatic cancer, probably representing an acute phase reactant. In the present study we determined the plasma levels of vWF antigen (vWF:Ag) by quantitative immunoelectrophoresis in 128 female patients with breast cancer as well as in 47 women with benign breast disease and in 27 healthy female controls. The levels of vWF:Ag were 170.7 ± 78 U/dl in patients with cancer, 148.4 ± 59 U/dl in patients with benign disease and 130.6 ± 45 U/dl in controls (P&lt;0.005). We also detected a significant increase in the...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Von Willebrand factor; Breast cancer; Malignancy.
Ano: 2001
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2001000900004

Polymorphism in the promoter region of von Willebrand factor gene and von Willebrand disease type 1
Provedor de dados: 74
Autores: Simon,Daniel; Bandinelli,Eliane; Roisenberg,Israel.
The -1185A/G polymorphism in the 5'-regulatory region of the von Willebrand factor (VWF) gene was associated with VWF plasma levels in a normal population. This study was undertaken to evaluate whether there is a relationship between this polymorphism and type 1 von Willebrand disease (VWD), a disorder characterized by a quantitative deficiency of VWF. The association between this polymorphism and plasma VWF levels in normal Brazilian individuals was also analyzed. Control subjects (n = 460) and type 1 VWD patients (n = 41) were studied. Polymerase chain reaction (PCR) amplification of the 864-bp VWF promoter region followed by AccII restriction-digestion was used to identify the -1185A/G genotypes. The -1185G allele frequency was 57% in normal individuals...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Von Willebrand factor; Promoter polymorphisms; Genetics; Von Willebrand disease.
Ano: 2003
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572003000400001